Vanda Pharmaceuticals, Inc. contends that the US Food and Drug Administration wrongly denied its request for fast track designation for tradipitant because it could not obtain safety data for chronic use of the drug in treating gastroparesis symptoms.
The company filed suit against the agency asking the US District Court for the District of Columbia to vacate the FDA’s denial of its request and declare that the agency...